Maxigen Biotech Inc. (1783.TW)
TWD 43.3
(-0.12%)
TWD 43.3
(-0.12%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | - TWD | 0.0% |
| 2022 | - TWD | -100.0% |
| 2021 | 7.27 Million TWD | -24.5% |
| 2020 | 9.64 Million TWD | -20.53% |
| 2019 | 12.13 Million TWD | 0.0% |
| 2018 | - TWD | -100.0% |
| 2017 | 13.24 Million TWD | -10.99% |
| 2016 | 14.87 Million TWD | -77.07% |
| 2015 | 64.87 Million TWD | -8.71% |
| 2014 | 71.06 Million TWD | -7.77% |
| 2013 | 77.04 Million TWD | -3.69% |
| 2012 | 80 Million TWD | 0.0% |
| 2011 | 80 Million TWD | 0.0% |
| 2010 | - TWD | 0.0% |
| 2009 | - TWD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | - TWD | 0.0% |
| 2024 Q1 | - TWD | 0.0% |
| 2023 Q3 | - TWD | 0.0% |
| 2023 Q2 | - TWD | 0.0% |
| 2023 FY | - TWD | 0.0% |
| 2023 Q1 | - TWD | 0.0% |
| 2023 Q4 | - TWD | 0.0% |
| 2022 Q2 | - TWD | -100.0% |
| 2022 Q1 | 6.68 Million TWD | -8.19% |
| 2022 FY | - TWD | -100.0% |
| 2022 Q4 | - TWD | 0.0% |
| 2022 Q3 | - TWD | 0.0% |
| 2021 Q3 | 7.87 Million TWD | -6.98% |
| 2021 Q4 | 7.27 Million TWD | -7.56% |
| 2021 Q1 | 9.05 Million TWD | -6.08% |
| 2021 FY | 7.27 Million TWD | -24.5% |
| 2021 Q2 | 8.46 Million TWD | -6.52% |
| 2020 Q4 | 9.64 Million TWD | -5.71% |
| 2020 FY | 9.64 Million TWD | -20.53% |
| 2020 Q1 | 11.48 Million TWD | -5.35% |
| 2020 Q2 | 10.83 Million TWD | -5.67% |
| 2020 Q3 | 10.22 Million TWD | -5.6% |
| 2019 Q1 | 14.08 Million TWD | 0.0% |
| 2019 Q2 | 13.43 Million TWD | -4.6% |
| 2019 Q3 | 12.77 Million TWD | -4.88% |
| 2019 Q4 | 12.13 Million TWD | -5.07% |
| 2019 FY | 12.13 Million TWD | 0.0% |
| 2018 Q3 | 212.7 Million TWD | 1613.53% |
| 2018 Q1 | 12.82 Million TWD | -3.13% |
| 2018 FY | - TWD | -100.0% |
| 2018 Q4 | - TWD | -100.0% |
| 2018 Q2 | 12.41 Million TWD | -3.24% |
| 2017 Q4 | 13.24 Million TWD | -3.01% |
| 2017 Q2 | 14.06 Million TWD | -2.82% |
| 2017 Q1 | 14.47 Million TWD | -2.73% |
| 2017 FY | 13.24 Million TWD | -10.99% |
| 2017 Q3 | 13.65 Million TWD | -2.92% |
| 2016 Q2 | 61.72 Million TWD | -2.52% |
| 2016 Q1 | 63.31 Million TWD | -2.4% |
| 2016 FY | 14.87 Million TWD | -77.07% |
| 2016 Q4 | 14.87 Million TWD | -2.6% |
| 2016 Q3 | 15.27 Million TWD | -75.25% |
| 2015 Q3 | 66.46 Million TWD | -2.26% |
| 2015 FY | 64.87 Million TWD | -8.71% |
| 2015 Q4 | 64.87 Million TWD | -2.39% |
| 2015 Q2 | 68 Million TWD | -2.2% |
| 2015 Q1 | 69.52 Million TWD | -2.16% |
| 2014 Q1 | 75.57 Million TWD | -1.91% |
| 2014 Q4 | 71.06 Million TWD | -2.08% |
| 2014 FY | 71.06 Million TWD | -7.77% |
| 2014 Q3 | 72.57 Million TWD | -2.03% |
| 2014 Q2 | 74.07 Million TWD | -1.98% |
| 2013 FY | 77.04 Million TWD | -3.69% |
| 2013 Q2 | 80 Million TWD | 0.0% |
| 2013 Q3 | 78.52 Million TWD | -1.84% |
| 2013 Q4 | 77.04 Million TWD | -1.89% |
| 2013 Q1 | - TWD | -100.0% |
| 2012 Q4 | 80 Million TWD | 0.0% |
| 2012 FY | 80 Million TWD | 0.0% |
| 2012 Q2 | 80 Million TWD | 0.0% |
| 2011 Q2 | 80 Million TWD | 0.0% |
| 2011 Q4 | 80 Million TWD | 0.0% |
| 2011 FY | 80 Million TWD | 0.0% |
| 2010 Q4 | - TWD | 0.0% |
| 2010 FY | - TWD | 0.0% |
| 2009 FY | - TWD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 12.56 Million TWD | 100.0% |
| SciVision Biotech Inc. | 346.69 Million TWD | 100.0% |
| Bionime Corporation | 1.69 Billion TWD | 100.0% |
| Pegavision Corporation | 365.09 Million TWD | 100.0% |
| Visco Vision Inc. | 848.86 Million TWD | 100.0% |